Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
pulmonary fibrosis/illamående
Länken sparas på Urklipp
Sida 1 från 83 resultat
Real-Life Experience with Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Nintedanib (Ofev(®)) inhibits receptor tyrosine kinases implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This article reviews the efficacy and tolerability of oral nintedanib in the treatment of IPF, as well as summarizing its pharmacological properties. In the randomized,
Oral lesions and pulmonary fibrosis after ingesting grapes.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A young rural man referred to us with profound icterus and dyspnea after he had eaten three grapes almost 10 days earlier. He had referred to a local hospital 30 min after ingestion with nausea, vomiting and abdominal pain and was conservatively managed. He then became icteric and began to
Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. Recently, pirfenidone was reported to slow the rate of decline in vital capacity and improve progression-free survival in IPF. The purpose of this study was to clarify the factors that
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Purpose: Pirfenidone and nintedanib are two novel antifibrotic agents licensed for the treatment IPF. Prior to being approved for use in England for patients with FVC >50% and <80%, these were made available for all IPF patients under the Mild Patient Program (MPP) and Patient In Need
Pirfenidone in idiopathic pulmonary fibrosis.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis for which, until recently, there were no effective treatments. Pirfenidone (5-methyl-1-phenylpyridin-2[1H]-one) is a novel antifibrotic agent that has been demonstrated to slow disease progression in patients with
Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Introduction. Angiosarcoma is a rare cancer of the inner lining of blood vessels and can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly patient, involving head and neck (H&N), especially the scalp. Pegylated liposomal doxorubicin (PLD) is one of the available
Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic fibrotic lung disease. Although the precise cause of the disease is still unknown, recent studies have shown that the pathogenesis of pulmonary fibrosis involves multiple mechanisms, with abnormal behavior of alveolar epithelial cells
Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a fatal condition with limited treatment options. However, in a previous small study, co-trimoxazole was found to be beneficial.
METHODS
In a double-blind multicentre study, 181 patients with fibrotic idiopathic interstitial pneumonia (89% diagnosed
Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis.
METHODS
We performed a
The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Pirfenidone: a review of its use in idiopathic pulmonary fibrosis.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Pirfenidone (Esbriet®) is an orally administered, synthetic, pyridone compound that is approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU, and for the treatment of IPF in the USA. This article summarizes pharmacological, efficacy and tolerability
Factor analysis identifies three separate symptom clusters in idiopathic pulmonary fibrosis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Idiopathic pulmonary fibrosis (IPF) is a severe and progressive lung disease with a poor prognosis. Patients with IPF suffer from a high symptom burden, which impairs their health-related quality of life (HRQoL). Lack of research on IPF symptoms and their clustering, however, makes symptom-centred
Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Background: In the phase III trial of nintedanib, only 10.8% of participants were aged ≥75 years. Here, we aimed to evaluate the tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis (IPF).
Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Chemotherapy with oxaliplatin and 5-fluorouracil (5-FU)/folinic acid is the standard first-line therapy of metastatic colorectal carcinoma and has shown activity in several other malignancies. This regimen is mostly well tolerated. Known side effects include myelosuppression,
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
